Nu Skin Enterprises, Inc. (NUS) Analysts See $0.96 EPS

October 14, 2018 - By Peter Erickson

Nu Skin Enterprises, Inc. (NYSE:NUS) LogoInvestors sentiment increased to 1.63 in 2018 Q2. Its up 0.21, from 1.42 in 2018Q1. It is positive, as 28 investors sold Nu Skin Enterprises, Inc. shares while 62 reduced holdings. 43 funds opened positions while 104 raised stakes. 39.98 million shares or 1.62% more from 39.34 million shares in 2018Q1 were reported.
Grp Incorporated One Trading Lp reported 2,869 shares. First Trust Limited Partnership stated it has 0.04% of its portfolio in Nu Skin Enterprises, Inc. (NYSE:NUS). Thrivent Finance For Lutherans accumulated 12,671 shares. Us Bancorp De reported 2,493 shares stake. The Switzerland-based Swiss National Bank & Trust has invested 0.01% in Nu Skin Enterprises, Inc. (NYSE:NUS). Raymond James & accumulated 22,703 shares or 0% of the stock. Robertson Opportunity Ltd has invested 4.08% of its portfolio in Nu Skin Enterprises, Inc. (NYSE:NUS). Comerica National Bank holds 0.02% of its portfolio in Nu Skin Enterprises, Inc. (NYSE:NUS) for 42,549 shares. Citadel Lc accumulated 13,400 shares. Bank Of Ny Mellon accumulated 817,003 shares or 0.02% of the stock. Rhode Island-based Washington has invested 0% in Nu Skin Enterprises, Inc. (NYSE:NUS). Schwab Charles Investment Mgmt invested 0.03% in Nu Skin Enterprises, Inc. (NYSE:NUS). Alpha Windward Limited Liability invested in 0.02% or 367 shares. Great West Life Assurance Company Can reported 31,897 shares stake. American Intll Grp owns 112,008 shares for 0.03% of their portfolio.

Since May 2, 2018, it had 0 insider buys, and 6 insider sales for $2.56 million activity. The insider OFFEN NEIL H sold 7,000 shares worth $571,620.

Analysts expect Nu Skin Enterprises, Inc. (NYSE:NUS) to report $0.96 EPS on November, 7.They anticipate $0.20 EPS change or 26.32 % from last quarter’s $0.76 EPS. NUS’s profit would be $53.31 million giving it 17.88 P/E if the $0.96 EPS is correct. After having $1.08 EPS previously, Nu Skin Enterprises, Inc.’s analysts see -11.11 % EPS growth. The stock increased 2.52% or $1.69 during the last trading session, reaching $68.66. About 429,857 shares traded or 3.62% up from the average. Nu Skin Enterprises, Inc. (NYSE:NUS) has risen 32.28% since October 14, 2017 and is uptrending. It has outperformed by 16.66% the S&P500.

Nu Skin Enterprises, Inc. (NYSE:NUS) Ratings Coverage

Among 3 analysts covering Nu Skin Enterprises (NYSE:NUS), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Nu Skin Enterprises had 3 analyst reports since April 30, 2018 according to SRatingsIntel. The stock has “Buy” rating by Citigroup on Monday, April 30. The rating was upgraded by Stifel Nicolaus to “Hold” on Friday, August 3.

Nu Skin Enterprises, Inc. develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. The company has market cap of $3.81 billion. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC Transformation anti-aging skin care systems; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products. It has a 26.25 P/E ratio. The firm also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, and LifePak nutritional supplements, as well as other anti-aging nutritional solutions and weight management products.

Another recent and important Nu Skin Enterprises, Inc. (NYSE:NUS) news was published by Globenewswire.com which published an article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within Ellington Residential Mortgage REIT, International …” on October 05, 2018.

Nu Skin Enterprises, Inc. (NYSE:NUS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>